Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




Zacks Analyst Blog Highlights: Dynavax Technologies Corp., Skyworks Solutions, Inc., Wilmington Trust Corp., Micromet Inc. and Embraer. – Press Releases

Zacks Market Commentaries (April 28th, 2009) Writes:
For Immediate Release

Chicago, IL - April 28, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Dynavax Technologies Corp. (DVAX),Skyworks Solutions, Inc. (SWKS), Wilmington Trust Corp. (WL), Micromet Inc. (MITI) and Embraer (ERJ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Dynavax Surge Not Warranted

In early morning trading, Dynavax Technologies Corp. (NASDAQ: DVAX) shares shot up dramatically (36%). However, we don't see a clear reason for that.

The surge may be related to two pieces of news: phase III Heplisav data and the swine

...

Dynavax Surge Not Warranted – Analyst Blog

Zacks Market Commentaries (April 27th, 2009) Writes:
Dynavax: Surge on Heplisav Phase III or Swine Flu? In early morning trading, Dynavax Technologies Corp. (DVAX) shares shot up dramatically (36%). However, we don't see a clear reason for that.The surge may be related to two pieces of news: phase III Heplisav data and the swine flu breakout.The first piece of news is about its phase III candidate Heplivsav. This morning, the company announced the oral presentation of additional phase III clinical data for Heplisav hepatitis B vaccine in a session for late-breaking abstracts at the 44th Annual Meeting of the European Association for the Study of Liver Disease (EASL) in Copenhagen, Denmark.In the presentation, Heplisav met its primary endpoint in this phase III trial and demonstrated the vaccine's potential to provide more rapid and increased protection against hepatitis B viral infection and with fewer doses than the licensed ...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.